Please login to the form below

Not currently logged in
Email:
Password:

Nancy Simonian joins board of Seattle Genetics

Former chief medical officer at Takeda subsidiary Millennium brings both clinical and regulatory experience

Nancy Simonian, former chief medical officer at Takeda subsidiary Millennium, has been appointed to the board of US biotech Seattle Genetics.

She spent ten years at Millennium from 2001 to 2011, leading clinical and regulatory activities, working on such product approvals as Velcade.

For the past year, she has worked as an independent consultant to the biotech industry.

“Nancy brings significant experience in all aspects of clinical development, regulatory affairs and medical research, as well as program management and strategic prioritization of product portfolios,” said Dr Clay Siegall, president and CEO of Seattle Genetics.

“She is a valuable addition to our Board as we continue executing on our broad clinical development program for Adcetris and advancing our pipeline of clinical and preclinical products aimed at improving treatments for people with cancer.”

Prior to her time at Millennium, Simonian was VP of clinical research at Biogen, as well as assistant professor of neurology at Massachusetts General Hospital and Harvard Medical School.

She said of her appointment: “I look forward to working with the Board and the management team to maximise the potential of Seattle Genetics' antibody-drug conjugate technology, collaborations and value to patients.”

27th March 2012

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Streaming Well

Streaming Well is a healthcare focused, award-winning video production company which operates in the US and Europe....

Latest intelligence

NHS regional footprints
What to expect from 2019...
Not another weight-loss ad
Christmas is over and the gyms are packed, it’s a never-ending tale. But why do we do it to ourselves every year?...
China’s clinical trial shake-up
As many of the obstacles to running clinical trials in China fall away, the country is proving to be a better research location...

Infographics